Stealth BioTherapeutics to Present at Upcoming Investor Conferences in May

Rhea-AI Summary

Stealth BioTherapeutics Corp (Nasdaq: MITO) announced that CEO Reenie McCarthy will present at two upcoming virtual investor conferences in May 2021. The conferences are: Oppenheimer's Rare & Orphan Disease Summit on May 21, 2021, from 9:55 to 10:35 a.m. ET, and UBS Global Healthcare Virtual Conference on May 26, 2021, from 10:00 to 10:45 a.m. ET. Live webcasts of the presentations will be available on Stealth's Investor Relations website, with replays archived for 30 days.

BOSTON, May 13, 2021 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that Reenie McCarthy, CEO, will present at the following upcoming virtual investor conferences in May:

Oppenheimer's Rare & Orphan Disease Summit
Date: Friday, May 21, 2021
Time: 9:55 – 10:35 a.m. ET

UBS Global Healthcare Virtual Conference
Date: Wednesday, May 26, 2021
Time: 10:00 – 10:45 a.m. ET

A live audio webcast of the presentations will be available on the Investors & News section of Stealth's website at https://investor.stealthbt.com/. A replay of the webcasts will be archived on Stealth's website for 30 days following the event.

About Stealth

We are a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases involving mitochondrial dysfunction. Mitochondria, found in nearly every cell in the body, are the body's main source of energy production and are critical for normal organ function. Dysfunctional mitochondria characterize a number of rare genetic diseases and are involved in many common age-related diseases, typically involving organ systems with high energy demands such as the heart, the eye, and the brain. We believe our lead product candidate, elamipretide, has the potential to treat both rare metabolic cardiomyopathies, such as Barth, Duchenne muscular dystrophy and Friedreich's ataxia, rare mitochondrial diseases entailing nuclear DNA mutations, as well as ophthalmic diseases entailing mitochondrial dysfunction, such as dry age-related macular degeneration and Leber's hereditary optic neuropathy. We are evaluating our second-generation clinical-stage candidate, SBT-272, and our new series of small molecules, SBT-550, for rare neurological disease indications following promising preclinical data. We have optimized our discovery platform to identify novel mitochondria-targeted compounds which may be nominated as therapeutic product candidates or utilized as mitochondria-targeted vectors to deliver other compounds to mitochondria.

Investor Relations
Stern Investor Relations
Janhavi Mohite, 212-362-1200
IR@StealthBT.com 

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/stealth-biotherapeutics-to-present-at-upcoming-investor-conferences-in-may-301291274.html

SOURCE Stealth BioTherapeutics Inc.

FAQ

What is Stealth BioTherapeutics presenting at the Oppenheimer's Rare & Orphan Disease Summit?

Stealth BioTherapeutics will present on May 21, 2021, from 9:55 to 10:35 a.m. ET.

When is the UBS Global Healthcare Virtual Conference?

The UBS Global Healthcare Virtual Conference is scheduled for May 26, 2021, from 10:00 to 10:45 a.m. ET.

Where can I watch the presentations from Stealth BioTherapeutics?

The presentations can be watched live on Stealth's Investor Relations website.

What is the ticker symbol for Stealth BioTherapeutics?

The ticker symbol for Stealth BioTherapeutics is MITO.

How long will the webcasts from Stealth BioTherapeutics be available?

The webcasts will be archived for 30 days following the events.